EGFR mutation in peripheral blood predicts EGFR TKIs effectiveness as the first-line therapy in advanced non-small cell lung cancer(NSCLC)

WANG Tong-fei,LI Xiao-hui,ZHANG Ju,ZHANG He-long

DOI: https://doi.org/10.3969/j.issn.1672-4992.2011.05.026

2011-01-01

Journal of Modern Oncology

Abstract:Objective: To study EGFR TKIs' therapeutic effect as the first-line therapy by determining the EGFR mutations in advanced NSCLC patients' peripheral blood.Methods:Peripheral blood from 51 patients with advanced NSCLC submitted to EGFR TKI drugs was determined by fluorescence polarization(TDI-FP) assay,the relationship between EGFR mutations in peripheral blood and the effectiveness of EGFR TKIs was analyzed.Results:The rate of EGFR mutation determined by TDI-FP in 51 patients' peripheral blood was 60.8%(31/51).After EGFR TKIs the first-line treatment,the overall response rate of mutational and wild type group were 41.9% and 5.0%,the disease control rate were 77.4% and 15.0%,and the median progression-free survival were 13.0 months and 7.0 months,respectively.Compared with the way of detecting EGFR mutations in tissue,the π of detecting EGFR mutations in peripheral blood by TDI-FP was 84.2%.NSCLC patients with EGFR mutations treated by EGFR TKIs as the first-line therapy achieved much better effectiveness.Conclusion:Determining the mutations of EGFR in advanced NSCLC patients' peripheral blood shows significant value in predicting the outcome of EGFR TKI drugs as the first-line therapy.